Clinical trials
Progressive Multiple Sclerosis clinical trials
Below are recruiting progressive multiple sclerosis clinical trials, each written for real people, not researchers. We’re tracking 132 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06846281RecruitingPhase 3
Remibrutinib for relapsing multiple sclerosis after switching from Ocrevus
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
Scottsdale, ArizonaAges 40–70 - NCT04694534Recruiting
Serious game program to help thinking skills in multiple sclerosis
This trial tests whether a computer “serious game” can improve thinking and memory skills in people with multiple sclerosis (MS). It’s designed for adults who report thinking problems and show weaker-than-average results on specific brain tests.
Arras, Hauts-de-FranceAges 18–65 - NCT07878923Recruiting
Early vs delayed treatment for relapsing multiple sclerosis
This study compares starting treatment with Ocrevus Zunovo right away versus waiting a bit for people who recently had a relapse. The goal is to see if starting sooner helps control the disease better.
Oklahoma City, OklahomaAges 18 years+ - NCT07161258RecruitingPhase 2
Fenebrutinib for children with relapsing MS
This study tests a new oral medication called fenebrutinib for children and teenagers with relapsing multiple sclerosis. It aims to find the right dose and see how safe and effective it is compared to standard treatments.
Rosario, Santa Fe ProvinceAges 10–17 - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55 - NCT07776743RecruitingPhase 2
Testing a new oral drug for relapsing-remitting multiple sclerosis (RRMS)
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Beijing, Beijing MunicipalityAges 18–65 - NCT07759115Recruiting
Music program to improve thinking in people with multiple sclerosis
This study tests a music-based program to see if it can help improve thinking and memory in people with multiple sclerosis. It is a small feasibility study to see if the program is practical and helpful.
Austin, TexasAges 18–80 - NCT07321093RecruitingPhase 3
A study of BCD-281 for relapsing-remitting MS
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
Nizhny NovgorodAges 18–55 - NCT02433028Recruiting
Long-term study for MS and related nervous system conditions
This is a long-term hospital study that follows people diagnosed with MS (and a few related conditions) to understand how disease changes over time. You may be asked to have regular check-ups, brain scans, and provide blood samples so researchers can track disease and treatment effects.
Aarau, Canton of AargauAges Any age - NCT07189325RecruitingPhase 3
Comparing two ways to manage relapsing-remitting MS
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
MontpellierAges 40 years+ - NCT03109288RecruitingPhase 1/Phase 2
Biomarker-guided combination treatment for residual multiple sclerosis activity
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
Bethesda, MarylandAges 18–120 - NCT07517185RecruitingPhase 2
Early aggressive treatment for relapsing multiple sclerosis
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
FalunAges 18–50 - NCT05962177Recruiting
Study of blood tests and scans in relapsing-remitting MS
This study follows adults with relapsing-remitting multiple sclerosis using MRI scans and blood tests. It aims to understand how the disease behaves and what markers in blood and imaging may relate to changes over time.
MontpellierAges 18–59 - NCT07086950Recruiting
Brain training game for thinking skills in multiple sclerosis
This study tests a fun brain-training game designed to improve thinking and memory in people with multiple sclerosis. It may help with everyday mental tasks like concentrating and processing information.
Lausanne, Canton of VaudAges 18 years+ - NCT07032129RecruitingPhase 1/Phase 2
Targeted cell therapy for multiple myeloma that returned or didn't respond
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Beijing, Beijing MunicipalityAges 21–90 - NCT07292480Recruiting
Monthly NfL monitoring for relapsing-remitting MS
This trial tests whether monthly blood tests for a nerve protein (NfL) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (RRMS) who are on certain first-line treatments. It aims to find out if this monitoring helps catch early signs of active disease before symptoms appear.
NiceAges 18–55 - NCT06715436Recruiting
Ketogenic diet for multiple sclerosis
This study tests whether a ketogenic diet can help people with multiple sclerosis. You would follow a special high-fat, low-carb diet for a period, and the researchers will check its effects on your symptoms and overall health.
PaviaAges 18–60 - NCT07058896Recruiting
Improving walking skills in progressive multiple sclerosis
This study tests a program to help people with progressive multiple sclerosis who have severe walking difficulty. It aims to see if the program is feasible and can improve motor skills.
Ferrara, FEAges 18–75 - NCT06203106Recruiting
NYSCF Scientific Discovery Biobank
This study collects blood, saliva, or skin samples from people with certain neurological conditions and from healthy volunteers to help researchers better understand and find treatments for these diseases.
New York, New YorkAges 4 weeks+ - NCT07609719RecruitingPhase 4
Switch to under-the-skin ocrelizumab for multiple sclerosis
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
Scottsdale, ArizonaAges 18–65 - NCT07064291Recruiting
Self-esteem support for people with multiple sclerosis
This trial tests a technique that uses word associations to help boost self-esteem in people with multiple sclerosis. If you have low self-esteem and are on oral MS treatment, this study might help you feel better about yourself.
GrenobleAges 18 years+ - NCT07058870Recruiting
Improving walking skills in progressive multiple sclerosis
This study is testing a new way to help people with progressive multiple sclerosis improve their walking and motor skills. If you have mild to moderate trouble walking and meet some other health criteria, you may be able to join.
Ferrara, FEAges 18–75 - NCT05162638Enrolling by invitation
Immune study in MS and healthy adults using a special tube
This study compares immune (defense system) “profiles” between people with multiple sclerosis (MS) and healthy volunteers. It involves a thoracic duct cannulation procedure and several MRIs to see how immune cells behave and whether a specific immune pattern is different in MS.
Philadelphia, PennsylvaniaAges 18–40 - NCT07135752Recruiting
Comparing digital tests in people with early MS or MRI signs
This trial studies whether digital tests can detect early changes in people with radiologically isolated syndrome (RIS) or multiple sclerosis (MS) who have normal neurological exams. It may help identify subtle symptoms earlier.
NiceAges 18–60
Hear when a new Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progressive multiple sclerosis?
- Yes. Clin2 currently lists 132 recruiting progressive multiple sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progressive multiple sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progressive multiple sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis (MS) - Relapsing-remitting
- Relapsing Multiple Sclerosis
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.